ClinicalTrials.gg
Not yet recruitingNCT07596979Updated May 19, 2026

Ginger in the Modulation of Inflammatory Cytokines and Oxidative Stress in Patients With Coronary Artery Disease

An interventional study of Ginger and Placebo in Coronary Artery Disease (CAD), Oxidative Stress and Inflammation, sponsored by Universidade Federal Fluminense. Not yet recruiting at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-19.

Sponsored by Universidade Federal Fluminense · Not applicable, Interventional, and Health services research

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 152 studies in Coronary Artery Disease with a site in Brazil — 22 open to participants now, 29 under way, 4 of them phase 3. Coronary Artery Disease · Brazil.

Planned enrollment
90th of 123
50 · median 100
Started
2026
with 7 others
No phase
67 of 152
14 open now
Primary completion
2027-12
later than 16 of 28 live
Registered
146th of 152
by date

Among the 152 studies in Coronary Artery Disease with a site in Brazil, this one is the 90th largest by planned enrollment of the 123 interventional ones that give a count, is one of 8 that started in 2026, is one of 67 with no phase, reaches primary completion later than 16 of the 28 other live ones, and was the 146th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

22 of the 152 studies in Coronary Artery Disease with a site in Brazil are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 152 studies in Coronary Artery Disease with a site in Brazil, or all of them as a file.
02

Study summary

The study aims to evaluate the effect of ginger supplementation on inflammatory cytokines and markers of oxidative stress in patients with Coronary Artery Disease (CAD). A longitudinal double-blind randomized clinical trial will be carried out, involving CAD participants for two months.

Read the detailed description

Ginger (Zingiber officinale Roscoe) contains phenolic compounds, such as gingerols, shogaols, and zingiberene, recognized for their antioxidant and anti-inflammatory properties, and may act as an adjuvant strategy in the prevention and management of CAD. However, there are no studies in CAD patients evaluating these data.

03

Conditions studied

  • Coronary Artery Disease (CAD)
  • Oxidative Stress
  • Inflammation

Keywords

  • ginger
  • coronary artery disease
  • inflammation
  • oxidative stress
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Both sexes
  • Over 18 years of age;
  • Diagnosed with Coronary Artery Disease: confirmed by coronary angiography, coronary computed tomography angiography, or functional testing with ischemic load);
  • Participants who are asymptomatic or have angina limited to functional class III will be considered;
  • Patients who have already undergone coronary revascularization and angioplasty may participate;
  • the last acute coronary event must have occurred more than one year ago.

Exclusion criteria

Exclusion Criteria:

  • Unstable Coronary Artery Disease;
  • Pre-operative coronary artery bypass grafting or awaiting elective angioplasty;
  • Unstable angina;
  • functional class III or higher;
  • Advanced chronic kidney disease ( \< 30 ml/min/1.73 m²);
  • Individuals with diseases.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Ginger Group

    Participants will receive 2 capsules per day, providing the ginger extract daily, at a dosage of 500mg.

    Dietary Supplement: Ginger

  • Placebo comparator
    Placebo Group

    The placebo group will receive the same amount of 500mg placebo, at the same time, containing corn starch.

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementGinger extractStudies of Ginger extractGinger extract pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will receive 2 capsules per day, providing the ginger extract daily, at a dosage of 500mg.

    Also known as: ginger extract

  • Dietary supplementPlacebo

    The placebo group will receive the same amount of 500mg placebo, at the same time, containing corn starch.

06

What researchers measure

Primary outcomes

  1. Change of inflammatory status in the participants

    Get blood samples to evaluate the supplementation effects in inflammatory biomarkers: interleukin 6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), C-reactive protein (CRP).

    Time frame: Baseline and 8 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Participant data will not be public to other research unless necessary.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Dec 2027, 19 months later.

Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 19 months is below that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2026
First posted
May 19, 2026
StartEst.
May 18, 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2028
Last update
May 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07596979
Lead sponsor
Universidade Federal Fluminense
Collaborators
Conselho Nacional de Desenvolvimento Científico e Tecnológico, Rio de Janeiro State Research Supporting Foundation (FAPERJ)
Responsible party
Sponsor
First posted
May 19, 2026
Start date
May 18, 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
May 19, 2026

Study contacts

Denise Mafra
Contact
dmafra30@gmail.com
+5521985683003
Ludmila Cardozo
Contact
ludmilacardozo@id.uff.br
+5521987333185
Ludmila cardozo
principal investigator · Universidade Federal Fluminense

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ginger extract

Start the discussion